Clinical trials: COVID-19 ARDS
COVID-19 Acute Respiratory Distress Syndrome, Respiration, Artificial
Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19
Flow controlled ventilation (FCV) is a fairly new mode of mechanical ventilation, consisting of a constant inspiratory and expiratory flow. Inspiration is thus comparable to volume controlled ventilation (VCV).
- Trial name
- VICAR (NCT04894214)
- Testing
- Arterial blood gas (ABG), Recording of hemodynamic monitoring, Recording of respiratory monitoring
- Where
- Belgium
- Volunteers
- 11 people
- Sponsor
- University Hospital, Antwerp
ARDS, COVID-19 Pneumonia
HRQOL of Life After ECMO Due to COVID-19.
We intend to prospectively investigate physical and mental state (HRQOL) by means of quantitative telephone interviews after hospital discharge in patients surviving COVID-19 ARDS and ECMO therapy.
- Conditions
- ARDS, COVID-19 Pneumonia, Extracorporeal Membrane Oxygenation
- Trial name
- NCT05531032
- Testing
- Phone Interview
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- Medical University of Vienna
SARS-CoV Infection, COVID 19
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients
The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and…
- Conditions
- SARS-CoV Infection, COVID 19, Acute Respiratory Distress Syndrome ARDS
- Trial name
- NCT04321616
- Testing
- Hydroxychloroquine, Remdesivir, (Standard of Care) SoC
- Where
- Norway
- Volunteers
- 700 people
- Sponsor
- Oslo University Hospital
COVID-19, Extracorporeal Membrane Oxygenation Complication
Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome
This study aims to investigate outcomes and predictors of outcome after extracorporeal membrane oxygenation (ECMO) therapy for severe acute respiratory syndrome (ARDS) in COVID-19 patients.
- Conditions
- COVID-19, Extracorporeal Membrane Oxygenation Complication, Acute Respiratory Distress Syndrome
- Trial name
- NCT04383678
- Testing
- Extracorporeal membrane oxygenation
- Where
- 11 sites in Finland, France and 4 more
- Volunteers
- 132 people
- Sponsor
- Helsinki University Central Hospital
Acute Respiratory Distress Syndrome Related to SARS-CoV-2
COronaVirus Induced Acute Respiratory Disease Syndrome During PREGnancy
Few data are available on the management of critically ill pregnant women with pneumonia related to SARS-CoV-2. In the absence of clear recommendations for the management of delivery, clinicians are faced with the risk of…
- Trial name
- COVADIS-PREG (NCT05193526)
- Testing
- No intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Sars-CoV2, ARDS
Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection
The purpose of this study is to evaluate if a postural recruitment maneuver (PRM) improves the aeration and distribution of lung ventilation in patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19…
- Trial name
- NCT04475068
- Testing
- Lateral Position (left and right lateral decubitus)
- Where
- Peru
- Volunteers
- 15 people
- Sponsor
- Hospital Nacional Edgardo Rebagliati Martins
COVID-19 Acute Respiratory Distress Syndrome
Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2?
the aim of the study is to assess safety and efficacy of prone position ventilation beyond the usual 16 hrs in patients with SARS-COV-2
- Trial name
- NCT05109624
- Testing
- prolonged prone position ventilation
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Ain Shams University
Coronavirus, SARS-CoV-2
Hemodynamic Characteristics of Patients With SARS-CoV-2
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern.
- Conditions
- Coronavirus, SARS-CoV-2, COVID-19, Acute Respiratory Distress Syndrome
- Trial name
- PiCCOVID (NCT04337983)
- Testing
- Transpulmonary thermodilution, Echocardiography
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Bicetre Hospital
COVID-19 Drug Treatment
Telmisartan for Treatment of COVID-19 Patients
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic.
- Trial name
- NCT04355936
- Testing
- Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
- Where
- 2 sites in Argentina
- Volunteers
- 400 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
SARS-CoV 2, COVID
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or…
- Conditions
- SARS-CoV 2, COVID, ARDS, ALI
- Trial name
- AVICOVID-3 (NCT05137795)
- Testing
- ZYESAMI™ (aviptadil acetate)
- Sponsor
- APR Applied Pharma Research s.a.
COVID-19, Organ Dysfunction Syndrome Sepsis
Mechanisms for Organ Dysfunction in Covid-19
The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
- Conditions
- COVID-19, Organ Dysfunction Syndrome Sepsis, Organ Dysfunction Syndrome, Multiple, Septic Shock
- Trial name
- UMODCOVID19 (NCT04316884)
- Where
- Sweden
- Volunteers
- 380 people
- Sponsor
- Uppsala University
COVID-19, ARDS
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
The analgesic and sedation requirements in critically ill patients with COVID-19 have yet to be described. There are various factors that are likely affecting the agents being utilized for analgesia and sedation in these patients…
- Conditions
- COVID-19, ARDS, Withdrawal Syndrome, Iatrogenic Disease
- Trial name
- NCT05336656
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- Wilkes University
COVID-19, SARS CoV 2 Virus
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in…
- Conditions
- COVID-19, SARS CoV 2 Virus, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- COVID-19 (NCT06402318)
- Testing
- A&M Breathalyzer PROTECT Kiosk
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Geneva Foundation
COVID-19 Pneumonia
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome.
- Trial name
- NCT04449588
- Testing
- BDB-001 Injection, Conventional treatment
- Where
- 12 sites in Bangladesh, China and 3 more
- Volunteers
- 369 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
ARDS, Human, Covid-19
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19
This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days…
- Trial name
- NCT04456361
- Testing
- Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords
- Where
- Mexico
- Volunteers
- 9 people
- Sponsor
- Instituto de Medicina Regenerativa
COVID-19, ARDS
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
To evaluate the safety and efficacy of intravenous administration of bone marrow derived extracellular vesicles, ExoFlo, versus placebo as treatment for moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) in patients…
- Trial name
- EXIT-COVID19 (NCT04493242)
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- Direct Biologics, LLC
Covid19, ARDS, Human
Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
Acute Respiratory Distress Syndrome (ARDS) reflects the hallmark of the critical course of coronavirus (COVID19). The investigators have recently shown that Exhaled Breath Particles (EBP) measured as particle flow rate (PFR) from…
- Conditions
- Covid19, ARDS, Human, ALI
- Trial name
- NCT04503057
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Lund University Hospital
COVID-19 Acute Respiratory Distress Syndrome, COVID-19
Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)
This phase IIb study, LEONARDO is a multicenter, randomized, double-blind, placebo- controlled, parallel group study, to assess the therapeutic efficacy and safety of Plerixafor in patients over 18 years of age, with acute…
- Trial name
- LEONARDO (NCT05411575)
- Testing
- Plerixafor 20 MG/ML [Mozobil]
- Where
- 14 sites in Bulgaria, France
- Sponsor
- 4Living Biotech
Covid19, Ultrasound
Lung Ultrasound in COVID-19 Patients
To assess the prognostic performance of an early global LUS score with respect to the mortality in ICU and duration of ventilation.
- Conditions
- Covid19, Ultrasound, ARDS
- Trial name
- LUS-COVID (NCT04487769)
- Where
- Netherlands
- Volunteers
- 137 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Covid19, ARDS
Assessment of Lung Mechanics in COVID-19 Acute Respiratory Distress Syndrome
This study is meant to assess the lung mechanics in SARS-CoV-2 induced acute respiratory failure. A precise characterisation of lung mechanics and heart-lung-interactions might allow a better understanding of SARS-CoV-2 induced…
- Trial name
- LungMechCoV-19 (NCT04597853)
- Testing
- Assessment of lung mechanics and heart-lung interactions
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University of Zurich